Susquehanna Fundamental Investments LLC Makes New $1.48 Million Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

Susquehanna Fundamental Investments LLC bought a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 201,185 shares of the company's stock, valued at approximately $1,477,000. Susquehanna Fundamental Investments LLC owned about 0.15% of Vir Biotechnology as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Vir Biotechnology by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 2,196,601 shares of the company's stock worth $16,127,000 after buying an additional 7,827 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Vir Biotechnology by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company's stock worth $14,059,000 after purchasing an additional 703,360 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Vir Biotechnology by 10.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,252,655 shares of the company's stock worth $9,194,000 after acquiring an additional 118,379 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Vir Biotechnology by 4.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,237,600 shares of the company's stock worth $9,084,000 after buying an additional 55,300 shares in the last quarter. Finally, Artisan Partners Limited Partnership acquired a new position in shares of Vir Biotechnology during the 4th quarter worth about $6,742,000. Institutional investors and hedge funds own 65.32% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on VIR shares. JPMorgan Chase & Co. lifted their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a research note on Thursday, January 9th. Needham & Company LLC restated a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday, February 27th. Morgan Stanley upgraded shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $10.00 to $20.00 in a research note on Thursday, January 9th. Barclays boosted their target price on Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group decreased their price target on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $33.57.

Insiders Place Their Bets

In other news, CEO Backer Marianne De sold 79,712 shares of the firm's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the transaction, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. This trade represents a 9.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director George A. Scangos sold 10,964 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the sale, the director now owns 708,295 shares of the company's stock, valued at $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 99,611 shares of company stock worth $663,525. 15.60% of the stock is owned by company insiders.

Vir Biotechnology Stock Performance

Shares of VIR stock traded down $0.28 on Tuesday, hitting $5.88. The stock had a trading volume of 276,633 shares, compared to its average volume of 1,329,992. Vir Biotechnology, Inc. has a 52-week low of $4.95 and a 52-week high of $14.45. The stock's 50 day moving average is $6.49 and its 200-day moving average is $8.00. The firm has a market capitalization of $811.13 million, a price-to-earnings ratio of -1.49 and a beta of 1.36.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. Equities analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).